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Staphylococcus aureus (SA) is a major community-acquired pathogen. The emergence of drug-resistant strains like, methicillin-
resistant SA (MRSA), poses stiﬀ challenges to therapeutic intervention. Passive immune-therapy with speciﬁc antibodies is being
activelyexaminedtotreatfulminantinfectionswithlimitedsuccess.Inthisstudy,wedemonstratethatP4,a28-aminoacidpeptide,
derivedfrompneumococcalsurfaceadhesinAalongwithpathogen-speciﬁcantibody(IVIG;P4therapy)issuccessfulinenhancing
theopsonophagocytickilling(OPK)ofS.aureusinvitro.WequestionedifitispossibletoexpandP4therapytotreatstaphylococcal
infections in vivo. P4 therapy in combination with IVIG rescued 7/10 morbidly ill S. aureus-infected mice while only 2/10 survived
in the control group.
1.Introduction
Staphylococcus aureus, a gram-positive bacterium, is a com-
mensal organism known to cause a wide range of hospital-
and community-acquired infections. It is also recognized
for immune evasion mechanisms and its ability to develop
multi-antibiotic resistance. The burden of staphylococcal
disease has increased worldwide with the emergence of com-
munity-acquired methicillin-resistant Staphylococcus aureus
(CA-MRSA) [1, 2]. Incidence of S. aureus bacteremia in the
United States ranges between 20 and 40 cases per 100,000
with the case fatality rates ranging from 19 to 24% [3]. CA-
MRSA rates have doubled in USA from the year 2000 to 2006
[4]. The major threats are the increase in the drug resistance
in S. aureus, the spread among community isolates, and the
l i m i t e dn e wd r u g sw i t hd e m o n s t r a b l ee ﬃcacy on the drug-
resistant isolates [3]. To address these challenges, we need to
develop new tools and/or to retune old tools with new tech-
niques. Therapeutic antibodies (passive immunotherapy)
which can enhance the host immune system’s ability to over-
come S. aureus infection are ideal candidates to be evaluated
as alternatives to combating this infection [5].
P4, a 28-amino acid peptide derived from pneumococcal
surface adhesin A, has enhanced in vitro opsonophagocytosis
in the presence of pathogen-speciﬁc IgG and rescued mice
from life-threatening pneumococcal infection (P4-therapy)
[6–8]. Recently, we have shown that P4-therapy can also be
used to rescue mice from serious secondary pneumococcal
infection following H1N1 viral infection in mice [9]. We
questioned if it is possible to use P4 therapy to treat staphyl-
ococcal infections in vivo?
2.MaterialsandMethods
2.1. Peptide Synthesis. The amino acid sequence of the pep-
tide designated as P4 was previously described [10, 11]. P4
peptide with free N- and C-terminus were synthesized and
lyophilized at CDC Core Facility, Atlanta, GA. P4 peptide
used in this study was synthesized in an ACT (Advanced
ChemTech)396multiplepeptidesynthesizerbyuseofstand-
ard and modiﬁed ﬂuorenylmethyloxycarbonyl (Fmoc) pro-
tocols [12–14] and analyzed for ﬁdelity of synthesis based on
the protocols previously described [15]. Lyophilized peptide2 International Journal of Microbiology
was resuspended in diethylpyrocarbonate- (DEPC-) treated
water, sonicated for 3 minutes for dissolution and stored at
−70◦C.Wederived2peptides,P6and/orP7fromP4sequen-
ce, and these peptides had no activation eﬀect on the eukary-
otic cells [11] .T h e s ep e p t i d e sw e r eu s e da sn e g a t i v ec o n t r o l s
in all in vitro experiments.
2.2. Species-Speciﬁc Antibodies Used in This Study. S. aureus-
speciﬁc polyclonal and monoclonal antibodies used in this
study are as follows: (1) gammaglobulin (IVIG, Gamunex,
Telecris, NC), a pooled human serum having reactivity with
a wide range of pathogens including S. aureus [8], (2) a rab-
bit polyclonal (ab35194, Abcam, Cambridge, MA) directed
towards the soluble and structural antigens of the S. aureus,
(3) rabbit polyclonal IgG directed towards the clumping fac-
tor A, ClfA of S. aureus, PAbClfA (courtesy Inhibitex, Inc,
Alpharetta, GA), and (4) humanized mouse monoclonal
anti-ClfA IgG, HM904 (courtesy Inhibitex, Inc, Alpharetta,
GA). Our in vitro experiment design involved direct compar-
ison of changes in opsonophagocytic killing or uptake in the
presence or absence of P4.
2.3. Opsonophagocytic Killing Assay. To assess the relevance
of P4 therapy to treat S. aureus infections, we used an in vitro
opsonophagocytic killing assay (OPKA) [16]. HL-60 prom-
yelocytic leucocytes diﬀerentiated into granulocytic lineage
or fresh human polymorphonuclear neutrophills (PMNs)
were used as eﬀector cells. S. aureus clinical isolates used in
this study were kindly provided by Dr. Joe Patti and Dr. John
Vernachio (Inhibitex, Inc, Alpharetta,GA). Colony blot was
used to screen three diﬀerent S. aureus strains, namely,
S. aureus strainL, strainN, and strainFB for the presence of
surface-exposed antigens that react with the polyclonal and
monoclonal antibodies listed above. Based on the colony
blot analysis (data not shown), S. aureus strainN was select-
ed for OPKA. While all three S. aureus strains reacted with
IVIG (Gamunex), S. aureus strainN was the only that reacted
with all four antibodies. P4 peptide solution (100μg/mL)
wasaddedtotheOPKAmixtureatthepreopsonizationstage,
and the control wells received 10μL DEPC water instead.
Opsonophagocytic killing of S. aureus strainN in the pre-
sence of strain-speciﬁc antibodies and complement without
P4 served as the control. Increase in opsonophagocytic kill-
ingofthebacteriumwhenP4wasaddedtothisreactionmix-
ture (bacteria, antibody, and complement) was calculated
andexpressedas%increaseovercontrol.Severalexperimen-
talcontrolsweremaintainedthatincludebacteriaalone,bac-
teria with either one of the OPKA components, (antibody,
complement, HL60 cells); or an incomplete combination
that lacks any of the listed components. None of these con-
trols results in the killing of bacteria. Since the primary
objective of this study is to demonstrate the eﬀect of P4 on
the opsonophagocytic killing of S. aureus strainN, these con-
t r o l sw e r en o ti n c l u d e di nt h eﬁ g u r e s .
2.4. Isolation of PMNs from Human Blood. Heparinized ven-
ous blood was obtained from the Emory Blood Donor Servi-
ces, Atlanta, GA. The Leukocyte separation kit, Histopaque-
1119 (Sigma, St. Louis, MO) was used to separate granulo-
cytes from the blood. Granulocytes were separated from the
blood according to the methodology recommended by the
manufacturer.
2.5. Mouse Strains. Mice (Mus musculus), strain Swiss Web-
ster (ND4-SW), were obtained from Charles River Laborato-
ries (Wilimington, MA, USA). Mice used in this study were
6–10 weeks old.
2.6. Intranasal Infection and P4 Therapy. Intranasal inocula-
tion of mice with S. aureus strainN and P4 therapy was per-
formed using protocols previously described, with minor
modiﬁcations [6, 8]. Female Swiss Webster mice (Charles
River Laboratories, Wilmington, MA) 6 to 10 weeks of age
wereusedinthisstudy.Allexperimentswereapprovedbythe
Institutional Care and Use Committee (IACUC) and con-
ducted according to the institutional ethical guidelines for
animal experiments and safety guidelines. All experiments
were repeated three times. Swiss-Webster mice (n = 50)
were infected intranasally with S. aureus strainN (∼1.1 × 107
cells/mouse). Our initial attempts to develop an intravenous
challenge model were unsuccessful due to the rapid patho-
genesis. Hence, we selected an intranasal challenge model
that provided a window between moribundity and rescue. At
15 hours after challenge, 40/50 mice were moribund (score
2).Moribundmiceweredividedintofourgroups(10/group)
that included three control groups (no treatment, P4 only,
and IVIG only) and P4 therapy group (P4 + IVIG). Treat-
ment control groups received two doses of IVIG (i.p;
100μL/mouse) or P4 (i.v; 100μg/mouse) at 15 hours and 24
hours after infection. These time points were chosen based
on pathogen-speciﬁc challenge and dosage optimization ex-
periments. Similarly, P4 therapy group received 2 doses of
IVIG (i.p; 100μL/mouse), followed 20 minutes later by P4
(i.v; 100μg/mouse). Treated and untreated animals were
monitored for disease symptoms and survival. Due to
IACUC limitations, we have only used IVIG for in vivo ex-
periments.
2.7. Score of Moribund Characteristics. Mice were monitored
and visually scored twice daily for moribund characteristics.
Mice were ranked on a scale of 5 to 0; 5 = healthy, nor-
mal coat, skin, eyes, breathing and activity/movement; 4 =
healthy, beginning to look sick, ruﬄed coat; 3 = sick, ruﬄ-
edcoat,decreasedactivity;2=verysick,ruﬄedcoat,decreas-
ed activity, eye secretions; 1 = near death, ruﬄed coat, little/
no activity, eye secretions, decreased breathing, hence eutha-
nized; 0 = dead.
2.8. Statistics. All in vitro and in vivo experiments were per-
formed in triplicate on three separate assay days unless speci-
ﬁed otherwise. Number of moribund animals after the treat-
ment was recorded till 80 hours and the data were computed
for signiﬁcant diﬀerence among various groups using t-test:
paired two samples for means (MS Excel 2003). Kaplan-
Meier analysis was applied to the survival data.International Journal of Microbiology 3
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Figure 1: P4-mediated enhancement of in vitro opsonophagocytic
killing of Staphylococcus aureus strainN. In vitro opsonophagocy-
tosis killing assay was performed with HL60-cells-derived granulo-
cytes. Addition of P4 increased the opsonophagocytic killing of
S.aureusstrainNinthepresenceofstrain-speciﬁcantibodies.Maxi-
mum enhancement (≥70%) was seen with HM904 over control
that had all OPKA components except P4 (P<0.05). Antibodies
used in this in vitro assay: Gamunex (IVIG), a pooled human
serum having reactivity with a wide range of pathogens including
S. aureus; ab35194, rabbit polyclonal directed towards the soluble
and structural antigens of the S. aureus; PAbClfA, rabbit polyclonal
IgG directed towards the clumping factor A, ClfA of S. aureus,a n d
HM904, humanized mouse monoclonal anti-ClfA IgG.
3. Results andDiscussion
P4 peptide, a 28-amino acid putative binding domain of
Pneumococcal surface adhesin A (PsaA), is a multilineage
cellular activator [11]. Here we have demonstrated that this
eukaryotic cellular activation potential in P4 peptide can be
exploited for rescuing mice from serious staphylococcal in-
fections.
The OPK assay demonstrates the presence of functional
antibodies in sera [17]. Requirement of target-speciﬁc func-
tional antibodies and complement supports the hypothesis
that P4 enhances opsonophagocytosis of the target bacteria
by the eﬀector cells. P4 peptide has no direct eﬀect on the
bacterium and has no deleterious eﬀect on human cells [11].
Additional experiments have shown that P4 peptide does not
directlyincreasetheintraphagocyticrespiratoryburstasseen
with OxyBURST-labelled bacterium [8] or reactive oxygen
species(ROS)production(datanotshown).P4enhancedthe
in vitro opsonophagocytic killing of S. aureus strainN in the
presence of species-speciﬁc antibody and complement. The
P4-mediated enhancement of OPK for S. aureus strainN was
observed with HL-60-derived granulocytes and fresh PMNs
from human peripheral blood (Figures 1 and 2). Among the
antistaphylococcal antibodies, maximum enhancement in
the opsonophagocytic killing of S. aureus strainN was seen
with the humanized anti-ClfA MAb (HM904) with the fresh
PMNs as the eﬀector cells (100% with 6.6μg/mL of IgG,
Figure 2).Previously,humanizedanti-ClfAmonoclonalanti-
body was shown to be eﬀective as a prophylactic to protect
lab animals from staphylococcal infection [5].
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Figure 2: P4-mediated enhancement of OPK of S. aureus
strainN with fresh PMNs isolated from human blood. In vitro
opsonophagocytosis killing assay was performed with human peri-
pheral blood PMN’s. Addition of P4 increased the opsonophago-
cytic killing of S. aureus strainN in the presence of strain-speci-
ﬁc antibodies. Maximum enhancement (≥100%) was seen with
HM904 over control that had all OPKA components except P4
(P<0.05). Antibodies used in this in vitro assay: Gamunex
(IVIG), a pooled human serum having reactivity with a wide range
of pathogens including S. aureus; ab35194, rabbit polyclonal dir-
ected towards the soluble and structural antigens of the S. aureus;
PAbClfA, rabbit polyclonal IgG directed towards the clumping
factor A, ClfA of S. aureus, and HM904, humanized mouse mono-
clonal anti-ClfA IgG.
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Figure 3: Survival of S. aureus-strainN-infected mice after P4-
treatment. P4 with serotype-speciﬁc IgG confers protection to
Swiss-Webster mice against intranasal S. aureus strainN challenge.
Intravenous injection of P4 (100μg/mouse) with Gammaglobulin
(100μL/mouse) at 15 and 24 hours after challenge provided highly
signiﬁcant protection (70%; P = 0.02) from S. aureus strainN
infection (Kaplan-Meier analysis).
To ascertain if the P4-mediated enhancement of opsono-
phagocytosis would translate into therapeutic beneﬁt, mouse
rescue studies were carried out. Seventy percent (7/10) of
mice that received P4 and IVIG therapy survived with com-
plete remission of symptoms compared to untreated control
group that had no survivors (P = 0.024, Figure 3). Even4 International Journal of Microbiology
though there was a diﬀerence in the number of animals that
survived in the single-treatment groups (P4 only = 40%;
IVIG only = 20%), these diﬀerences were not statistically sig-
niﬁcant (P = 0.33). In this study, we have shown that P4-
therapy combined with IVIG is eﬀective in rescuing mice
from severe S. aureus infection. The data suggest that P4 may
be an important adjunct to immune therapy.
TheP4-mediatedrescueofmiceislikelyduetoactivation
of circulating eﬀector cells leading to an increase in the num-
ber of phagocytic cells participating in the opsonophagocytic
clearance of the bacterial pathogen. We have hypothesized a
mechanism of P4-therapy [18]; although the exact mecha-
nismisstillunderinvestigation, previousstudiessuggestthat
P4 therapy augments innate immunity [9]. Polymorphonu-
clearneutrophils(PMNs)arethemajorinnateimmunecom-
ponent activated by P4 peptide as we have observed that
micetreatedwithaneutrophil-depletingantibody,RB6-8C5,
failed to respond to in vivo P4 therapy [7]. Recently, we have
demonstrated that both altered traﬃcking and enhanced
capacity of professional phagocytes are also associated with
the potential protective mechanism for P4-therapy [9]. We
havealsoobservedrapidclearanceofbacteriaassociatedwith
decreased surface display of FcγRI and FcγRII on phagocytes
[9]. In short, the presence of pathogen-speciﬁc antibody,
eﬀector cells, and complement are the critical factors that
determine the eﬀectiveness of P4 therapy against a particular
pathogen [8].
4. Conclusions
Staphylococcus aureus continues to be a problem pathogen
owing to its broad range of virulence factors and drug resis-
tance. Passive immune-therapy (IVIG) with immune-en-
hancingagentslikeP4peptideprovidesaviablealternativeto
treat S. aureus. Because of the high burden of staphylococcal
disease and high case fatality rate, these ﬁndings merit fur-
ther exploration.
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